This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

Name of Committee: National Institute of Neurological Disorders and Stroke Special Emphasis Panel; Spotrias.

Date: December 13–14, 2007.

Time: 8 a.m. to 7 p.m.

Agenda: To review and evaluate grant applications.

Place: Mandarin Oriental Hotel, Washington, DC, 1330 Maryland Avenue, SW, Washington, DC 20024.

Contact Person: Shanta Rajaram, PhD, Scientific Review Administrator, Scientific Review Branch, Division of Extramural Research, NINDS/NIH/DHHS/Neuroscience Center, 6001 Executive Blvd., Suite 3208, MSC 9529, Bethesda, MD 20852, 301–435–6033, rajarams@mail.nih.gov.

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

(Catalogue of Federal Domestic Assistance Program Nos. 93.853, Clinical Research Related to Neurological Disorders; 93.854, Biological Basis Research in the Neurosciences, National Institutes of Health, HHS)

Dated: November 26, 2007
Jennifer Spaeth,
Director, Office of Federal Advisory Committee Policy.

[FR Doc. 07–5913 Filed 12–3–07; 8:45 am]
BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health

National Institute of Mental Health Draft Strategic Plan

AGENCY: National Institute of Mental Health, NIH, HHHS.

ACTION: Notice.

SUMMARY: The National Institute of Mental Health (NIMH) is developing a strategic plan for the next 3–5 years, and invites the public to provide comments on a draft of this plan. The draft plan will be publicly available through the NIMH Draft Strategic Plan Web page (http://www.nimh.nih.gov/about/strategic-planning-reports/nimh-draft-strategic-plan.shtml) from November 20, 2007 through December 21, 2007. The public is invited to provide comments via the e-mail address or the postal address listed on the NIMH Draft Strategic Plan Web page.

Background: NIMH is the lead Federal agency for research on mental and behavioral disorders and has as its mission to reduce the burden of these disorders through research on mind, brain, and behavior. The Institute’s goal is to generate research that will transform the prevention of and recovery from mental disorders. To inspire and support research that will make a difference for those living with mental illness, the Institute is developing a Strategic Plan to help direct this complex research effort and bring into sharper focus the methods, questions, and perspectives that will transform the diagnosis, treatment, and prevention of mental disorders, ultimately paving the way toward cures.

NIMH’s draft Strategic Plan outlines several Strategic Objectives that will guide the research agenda for the Institute over the next several years. The public is invited to review this draft plan and provide comments between November 20, 2007 and December 21, 2007. The draft plan may be viewed at http://www.nimh.nih.gov/about/strategic-planning-reports/nimh-draft-strategic-plan.shtml, and hard copies are available by calling 1–866–615–6464 (toll free) or by sending a letter requesting a copy (that includes your mailing address) to: National Institute of Mental Health, Attn: Draft Strategic Plan, 8280 Greensboro Drive, Suite 300, McLean, Virginia 22102.

Request for Comments: The public is invited to provide comments on the draft Strategic Plan. Comments may be sent to the email address listed on the NIMH Strategic Planning Web page at http://www.nimh.nih.gov/about/strategic-planning-reports/nimh-draft-strategic-plan.shtml, or sent to the postal address listed above.

FOR FURTHER INFORMATION CONTACT: Additional information is posted on the NIMH Strategic Planning Web page, located at http://www.nimh.nih.gov/about/strategic-planning-reports/nimh-draft-strategic-plan.shtml.

Comments Due Date: Comments regarding the draft of NIMH’s strategic plan should be submitted via e-mail no later than December 21, 2007. Comments mailed to the above postal address must be postmarked by the same date.

Thomas Insel,
Director, National Institute of Mental Health, National Institutes of Health.

[FR Doc. E7–23420 Filed 12–3–07; 8:45 am]
BILLING CODE 4149–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Substance Abuse and Mental Health Services Administration

Current List of Laboratories Which Meet Minimum Standards To Engage in Urine Drug Testing for Federal Agencies

AGENCY: Substance Abuse and Mental Health Services Administration, HHHS.

ACTION: Notice.

SUMMARY: The Department of Health and Human Services (HHS) notifies Federal agencies of the laboratories currently certified to meet the standards of Subpart C of the Mandatory Guidelines for Federal Workplace Drug Testing Programs (Mandatory Guidelines). The Mandatory Guidelines were first published in the Federal Register on April 11, 1988 (53 FR 11970), and subsequently revised in the Federal Register on June 9, 1994 (59 FR 29908), on September 30, 1997 (62 FR 51118), and on April 13, 2004 (69 FR 19644).

A notice listing all currently certified laboratories is published in the Federal Register during the first week of each month. If any laboratory’s certification is suspended or revoked, the laboratory will be omitted from subsequent lists until such time as it is restored to full certification under the Mandatory Guidelines.

If any laboratory has withdrawn from the HHS National Laboratory Certification Program (NLCP) during the past month, it will be listed at the end, and will be omitted from the monthly listing thereafter.

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Child Health and Human Development, Amended Notice of Meeting

Notice is hereby given of a change in the meeting of the National Institute of Child Health and Human Development Special Emphasis Panel, December 4, 2007, 1 p.m. to December 4, 2007, 5 p.m., National Institutes of Health, 6100 Executive Boulevard, 5B01, Rockville, MD, 20852 which was published in the Federal Register on November 16, 2007, 72 FR 64658.

The meeting will be held on December 5, 2007. The meeting is closed to the public.

Jennifer Spaeth,
Director, Office of Federal Advisory Committee Policy.

[FR Doc. 07–5914 Filed 12–3–07; 8:45 am]
BILLING CODE 4140–01–M
Road, Lenexa, KS 66215

Ave., Nashville, TN 37210, 615

585

Bayshore Clinical Laboratory).

Air Center Cove, Suite 101, Memphis,

Memphis, TN 38133.

Mearns Road, Warminster, PA 18974,


Dyncare Kasper Medical Laboratories,* 10150–102 St., Suite 200,

Edmonton, Alberta, Canada T5J 5E2,


ElSohly Laboratories, Inc., 5

Industrial Park Drive, Oxford, MS


Gamma-Dynacare Medical Laboratories,* A Division of the

Gamma-Dynacare Laboratory Partnership, 245 Pall Mall Street,

London, ONT, Canada N6A 1P4, 519–

679–1630.

Kroll Laboratory Specialists, Inc.,

1111 Newton St., Gretna, LA 70053,

504–361–8989/800–433–3823,

(Formerly: Laboratory Specialists, Inc.).

Kroll Laboratory Specialists, Inc., 450

Southlake Blvd., Richmond, VA 23236,

804–378–9130, (Formerly: Scientific

Testing Laboratories, Inc.; Kroll

Scientific Testing Laboratories, Inc.).

Laboratory Corporation of America

Holdings, 7207 N. Gessner Road,

Houston, TX 77040, 713–856–8288 /

800–800–2387.

Laboratory Corporation of America

Holdings, 69 First Ave., Raritan, NJ

08869, 908–526–2400 / 800–437–4986,

(Formerly: Roche Biomedical

Laboratories, Inc.).

Laboratory Corporation of America

Holdings, 1904 Alexander Drive,

Research Triangle Park, NC 27709, 919–

572–6900 / 800–833–3984. (Formerly:

LabCorp Occupational Testing Services, Inc.,

ComputChem Laboratories, Inc.;

ComputChem Laboratories, Inc., A

Subsidiary of Roche Biomedical

Laboratory; Roche ComputChem

Laboratories, Inc., A Member of the

Roche Group).

Laboratory Corporation of America

Holdings, 13112 Evening Creek Drive,

Suite 100, San Diego, CA 92128, 858–

668–3710 / 800–882–7272, (Formerly:

Poisonlab, Inc.).

Laboratory Corporation of America

Holdings, 550 17th Ave., Suite 300,

Seattle, WA 98122, 206–923–7020,

800–898–0180, (Formerly: DrugProof,

Division of Dynacare/Laboratory of

Pathology, LLC; Laboratory of

Pathology of Seattle, Inc.; DrugProof,

Division of Laboratory of Pathology of

Seattle, Inc.).

Laboratory Corporation of America

Holdings, 7500 Westpark Dr., Southaven,

MS 38671, 866–827–8042 / 800–233–

6339, (Formerly: LabCorp Occupational

Testing Services, Inc.; MedExpress/

National Laboratory Center).

LabOne, Inc. d/b/a Quest Diagnostics,

10101 Renner Blvd., Lenexa, KS 66219,

913–888–3927 / 800–873–8845,

(Formerly: Quest Diagnostics

Incorporated; LabOne, Inc.; Center for

Laboratory Services, a Division of

LabOne, Inc.).

MAXXAM Analytics Inc.*, 6740

Campbell Road, Mississauga, ON,

Canada L5N 2L8, 905–817–5700,

(Formerly: NOVAMANN (Ontario), Inc.).

MedTox Laboratories, Inc., 402 W.

County Road D, St. Paul, MN 55112,


MetroLab-Legacy Laboratory Services,

1225 NE 2nd Ave., Portland, OR 97232,


Minneapolis Veterans Affairs Medical

Center, Forensic Toxicology Laboratory,

1 Veterans Drive, Minneapolis, MN

55417, 612–725–2088.

National Toxicology Laboratories,

Inc., 1100 California Ave., Bakersfield,

CA 93304, 661–322–4250 / 800–350–

3515.

One Source Toxicology Laboratory,

Inc., 1213 Genoa-Red Bluff, Pasadena,

TX 77504, 888–747–3774, (Formerly:

University of Texas Medical Branch,

Clinical Chemistry Division; UTMB

Pathology-Toxicology Laboratory).

Oregon Medical Laboratories, 123

International Way, Springfield, OR

97477, 541–341–8092.

Pacific Toxicology Laboratories, 9348

DeSoto Ave., Chatsworth, CA 91311,

800–328–6942, (Formerly: Centinela

Hospital Airport Toxicology Laboratory).

Pathology Associates Medical

Laboratories, 110 West Cliff Dr.,

Spokane, WA 99204, 509–755–8991 /

800–541–7891x7.

Phamatech, Inc., 10151 Barnes

Canyon Road, San Diego, CA 92121,

858–643–5555.

Physicians Reference Laboratory,

7800 West 110th St., Overland Park, KS


Quest Diagnostics Incorporated, 3175

Presidential Dr., Atlanta, GA 30340,

770–452–1590 / 800–729–6432,

(Formerly: SmithKline Beecham Clinical

Laboratories; SmithKline Bio-Science

Laboratories).

Quest Diagnostics Incorporated, 400

Egypt Road, Norristown, PA 19403,

610–631–4600 / 877–642–2216,

(Formerly: SmithKline Beecham Clinical

Laboratories; SmithKline Bio-Science

Laboratories).

Quest Diagnostics Incorporated, 7600

Tyrone Ave., Van Nuys, CA 91405, 866–

370–6695 / 818–899–2521, (Formerly:

SmithKline Beecham Clinical

Laboratories).
The Docket Management Facility maintains the public docket for this notice. Comments and material received from the public, as well as documents mentioned in this notice as being available in the docket, will become part of this docket and will be available for inspection or copying at room W12–140 on the West Building Ground Floor, 1200 New Jersey Avenue, SE., Washington, DC, between 9 a.m. and 5 p.m., Monday through Friday, except Federal holidays. You may also find this docket on the Internet at http://www.regulations.gov.

A copy of the complete ICR is available through this docket on the Internet at http://www.regulations.gov. Additionally, copies are available from Commandant (CG–611), U.S. Coast Guard Headquarters, (Attn: Mr. Arthur Requina), 2100 2nd Street, SW., Washington, DC 20593–0001. The telephone number is (202) 475–3523.

FOR FURTHER INFORMATION CONTACT: Mr. Arthur Requina, Office of Information Management, telephone (202) 475–3523 or fax (202) 475–3929, for questions on these documents. Contact Ms. Renee V. Wright, Program Manager, Docket Operations, (202) 366–9826, for questions on the docket.

SUPPLEMENTARY INFORMATION:
The Coast Guard invites comments on the proposed collection of information to determine if it is necessary in the proper performance of Departmental functions. In particular, the Coast Guard would appreciate comments addressing:
(1) The practical utility of the collection;
(2) the accuracy of the estimated burden of the collection;
(3) ways to enhance the quality, utility, and clarity of information subject to the collection; and
(4) ways to minimize the burden of collection on respondents, including the use of automated collection techniques or other forms of information technology.

Comments to the FDMS or OIRA must contain the OMB Control Number of the ICR addressed. Comments must contain the docket number of this request, [USCG–2007–28578]. For your convenience, comments to OIRA to be considered, it is best if they are received on or before the January 3, 2008.